Doc Gumshoe checks in on PCSK9 inhibitors, statins, and blood pressure
19 Comments Read MoreArticles
Bulletins from the Cardiac Front
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
$MDCO, $AMGN, $SNY, $ESPR "Cardiologist Dr. Milton Packer recently posed a provocative question on his Revolution and R...
$PCSK9 $ESPR $AMGNNew findings reported today at the ESC Congress:"PCSK9 Is A Co-Activator Of Platelet Function ...
$ESPR PCSK9 inhibitors still too pricey, study finds... http://www.biopharmadive.com/news/amgen-repatha-pcsk9-cost-eff...
The most common types of cardiovascular disease include hypertension, ischemic heart disease, cerebrovascular disease (s...
And one more from biopharma drive:"This could either be due to lower than expected efficacy, adverse events seen in ...
$ESPR $AMGN #CVOT ESPR dropped 26% in early trading, presumably a victim of the cardiovascular outcome report on Repath...
$ESPR $PHE"Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor"Tuesday, ...
ESPR. Per A.F. "Talk of serious brain infections tied to AMGN, REGN, PFE, PCSK9 inhibitors prompting FDA meetings circ...
$ESPR :) New Cholesterol Drugs Won't Be Budget Busters -Express ScriptsBy Reuters Staff October 01, 2015NEW YOR...
$ESPR. Here's my question: Are the FDA's views as articulated in ESPR's release different from those the agency appli...
Re: $ESPR, they didn't say that a CVOT was going to be required, but are doing the CVOT in case there is concern at the ...
On drug pricing… A lead article in today’s Boston Globe describes efforts by an independent group- the Institute fo...
On drug pricing... A lead article in today's Boston Globe describes efforts by an independent group- the Institute for ...
Implications for $ESPR? It looks like CVS is pulling out all the stops in its fight to thwart the use of PCSK9 inhibit...
File this one as interesting, but who and what does one believe anymore. This study shows that statins do not appear to...
$ESPR (lonG) Great Hobbesian analysis! Clearly supportive of the KSS investment thesis on $ESPR - so much so, that I ...
Dr. KSS, This magnificent column answers the initial questions we began to formulate yesterday in light of the FDA ruli...
I see this Forbes article from Matt saying $ESPR needs to worry since they may need large trials.http://www.forbes.c...
Fox News just (about 2:00 pm) aired a fairly comprehensive piece (about 5 minutes) on PCSK9 Inhibitors. The motivation f...
Doc $ESPR i expect data in March too. There is so much catalyst for them this year. From Stifel upgrade to $90 early th...
Denis: I personally am staying in $ESPR and even considering adding. It exceptionally has the wind at its back now, and ...
Dr. KSS what is your take on this article. Thanks!Merck's minuscule benefit keeps cholesterol-lowering hypothesis al...
"The distinction between primary and secondary prevention is more pragmatic than absolute."Uh, no. Primary preventio...
One issue I see when discussing topics like this is that people cite 1 or a couple cases (for example, themselves) as pr...
Nice commentary Michael.Alnylam is merely waiting to see if, in an evidence-based-medicine way, the PCSK9 inhibitors...
Dr. KSS, You mentioned earlier about using PCSK9 inhibitors to treat high LDL. Amgen and Regeneron/ Sanofi have drugs i...